Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810232 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CASRADORA2AADORA3ADORA1 | |
| SCHEMBL21751457 | 0.92 | L3MBTL1 (0.34) | ALDH1A1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL21751336 | 0.92 | ADORA3 (0.41) | ALDH1A1CASRADORA2AADORA3ADORA1 | |
| SCHEMBL21751327 | 0.91 | LMNA (0.35) | ALDH1A1CASRADORA2AADORA3ADORA1 | |
| SCHEMBL30800134 | 0.91 | LMNA (0.35) | ALDH1A1CASRADORA2AADORA3ADORA1 | |
| SCHEMBL2670126 | 0.91 | ALDH1A1 (0.39) | ALDH1A1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL5560844 | 0.90 | ALDH1A1 (0.37) | ALDH1A1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL20211740 | 0.90 | KEAP1 (0.39) | ALDH1A1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL30800214 | 0.90 | KEAP1 (0.39) | ALDH1A1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL19810311 | 0.89 | ADORA2A (0.35) | ALDH1A1ADORA2AADORA2BKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| CN-119955899-A | Compositions, methods and kits for stabilizing coelenterazine and analogs and derivatives thereof | 普洛麦格公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-112996923-B | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | 普洛麦格公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024217576-A1 | FUSION POLYPEPTIDE AND KIT FOR DETECTING PROCALCITONIN AND USE THEREOF | 深圳琅技生命科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| CN-118139895-A | Luminescence-based antigen assay | 巴斯德研究所 | 2024-06-04 | — | — | CN | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115461454-A | Luciferase coupled immunosorbent assay | 巴斯德研究所 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | ALDH1A1 972/4885CASR 3490/4885ADORA2A 1755/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | ALDH1A1 659/4885CASR 3148/4885ADORA2A 1256/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | ALDH1A1 1484/4885CASR 1997/4885ADORA2A 1556/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | ALDH1A1 972/4885CASR 3490/4885ADORA2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.